Annual Revenue Comparison: HUTCHMED (China) Limited vs Xencor, Inc.

A Tale of Two Biotechs: Revenue Trends from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and innovation. Over the past decade, HUTCHMED (China) Limited and Xencor, Inc. have showcased contrasting revenue trajectories. HUTCHMED's revenue surged by over 800% from 2014 to 2023, reflecting its strategic expansion and robust pipeline. In contrast, Xencor, Inc. experienced a more modest growth of approximately 170% during the same period, highlighting its steady yet less aggressive market approach.

Key Insights

• HUTCHMED's Growth: From 2014 to 2023, HUTCHMED's revenue increased from around $92 million to $838 million, marking a significant leap in its market presence.
• Xencor's Steady Climb: Xencor's revenue rose from about $9.5 million in 2014 to $168 million in 2023, indicating consistent growth.

These trends underscore the diverse strategies and market dynamics within the biotech sector.